Trial Profile
Clinical Pharmacology study for AS-3201 in hepatic impairment subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Ranirestat (Primary)
- Indications Diabetic neuropathies
- Focus Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 12 May 2020 Results evaluating pharmacokinetics and safety of Ranirestat in patients with Hepatic Impairment, published in the Journal of Clinical Pharmacology
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2016 New trial record